Covalon Announces Conference Call to Discuss Third Quarter Financial Results

On August 21, 2020 Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, reported that it will be releasing its Fiscal 2020 Third Quarter financial results on Monday August 24th, 2020, before markets open (Press release, Covalon Technologies, AUG 21, 2020, View Source [SID1234563933]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A conference call to discuss Covalon’s Fiscal 2020 Q3 Financial Results will be held on Monday August 24th, 2020, at 9:00am EST. To participate in the call, please dial:

Local: 416.764.8659
North American Toll-Free: 1.888.664.6392
Confirmation Number: 80896464

A recording of the call will be available until September 7th, 2020, by calling 416.764.8677 or 1.888.390.0541 and entering the encore replay entry code 896464#. A recording of the call will also be available at View Source

Copies of Covalon’s financial statements and MD&A can be obtained on SEDAR at www.sedar.com, as well as at View Source

ONO Receives a Supplemental Approval in Japan for Velexbru Tablet 80mg, a BTK Inhibitor, for Additional Indication of Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma

On August 21, 2020 Ono Pharmaceutical Co., Ltd. reported that ONO received a supplemental approval for Velexbru (generic name: tirabrutinib hydrochloride) Tablet 80mg ("Velexbru"), a Bruton’s tyrosine kinase ("BTK") inhibitor, in Japan for additional indication of Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma, for a partial change in approved items of the manufacturing and marketing approval (Press release, Ono, AUG 21, 2020, View Source [SID1234584587]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval is based on the result from a multi-center, open-label, single-arm Phase II study (ONO4059-05), evaluating Velexbru in patients with previously untreated, or relapsed or refractory Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL). In 27 patients who received tirabrutinib (untreated 18 patients and relapsed or refractory 9 patients) in this study, the overall response rate (partial response or greater) assessed by an independent review committee (IRC), a primary endpoint, was 88.9% (16/18 patients) (95% CI: 65.3 – 98.6) in the untreated group, and 88.9% (8/9 patients) (95% CI: 51.8 – 99.7) in the relapsed/refractory group. The secondary endpoints of progression-free survival (PFS) and overall survival (OS) were 100% at 6 months both in the untreated group and relapsed/refractory group. The most commonly observed grade ≥3 adverse events (AEs) were neutropenia and lymphopenia (11.1% each), and leukopenia (7.4%).

With this approval, Velexbru becomes the first BTK inhibitor approved for the treatment of patients with previously untreated, relapsed or refractory WM and LPL in Japan. Velexbru was designated as an orphan drug for the indication of WM and LPL by the Ministry of Health, Labour and Welfare (MHLW) in Japan on November 19, 2019.

About Waldenstrom macroglobulinemia ("WM") and lymphoplasmacytic lymphoma ("LPL") WM and LPL are one of the malignant lymphomas and are classified as "indolent lymphoma" which means one with relatively slow progression*1. It is estimated that there are approximately 240 new cases* 2,3 with LPL per year in Japan. WM and LPL generally grow and spread slowly in the clinical course, with a median survival of more than 5 years, but these are intractable diseases that cannot be cured with existing therapies*4. In Japan, standard treatment has not been established in patients with untreated relapsed or refractory WM and LPL, so a new treatment option is expected for these patient populations.

About ONO-4059-05 Study This study is a multi-center, open-label, single-arm Phase II study, evaluating the efficacy and safety of a monotherapy with Velexbru in patients with previously untreated, or relapsed or refractory WM and LPL. In this study, 27 patients were recruited (untreated 18 patients and relapsed or refractory 9 patients). Patients received Velexbru 480 mg (fasted) once daily and were treated until disease progression or unacceptable toxicity. The primary endpoint of this study is the overall response rate (partial response or greater) assessed by an independent review committee (IRC). The secondary endpoints are progression-free survival (PFS) and overall survival (OS).

About Velexbru Velexbru (tirabrutinib hydrochloride), discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B cell receptor ("BCR") signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B cell lymphocyte. The BCR signaling pathway is known to be permanently activated, particularly B cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). Velexbru is expected to have a therapeutic effect because it inhibits BTK, a mediator located downstream of BCR. In December 2014, ONO out-licensed Tirabrutinib to Gilead Sciences, Inc. (Gilead) to allow Gilead the right to develop and commercialize the product in all countries of the world, except Japan, South Korea, Taiwan, China and ASEAN countries where ONO retains the development and commercialization rights of the product. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL).

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On August 21, 2020 Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, reported the closing of its previously announced initial public offering of 8,050,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares, at a price to the public of $17.00 per share (Press release, Inhibrx, AUG 21, 2020, View Source [SID1234563934]). The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $136.9 million. All of the shares of common stock were sold by Inhibrx.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Inhibrx’s common stock began trading on the Nasdaq Global Market on August 19, 2020 under the symbol "INBX".

Jefferies, Evercore ISI and Credit Suisse acted as joint book-running managers for the offering. LifeSci Capital acted as co-manager for the offering.

Registration statements relating to these securities became effective on August 18, 2020. This offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Evercore Group, L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast – correction

On August 21, 2020 Nordic Nanovector ASA (OSE: NANO) reported that it will report its results for the second quarter and first half 2020 on Thursday, 27 August 2020 (Press release, Nordic Nanovector, AUG 21, 2020, View Source;correction-301116398.htm [SID1234563935]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation by the Nordic Nanovector’s senior management team will take place the same day at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, Meeting Room: Vika Auditorium.

The presentation will be a live webcast, and a recording will then be available at www.nordicnanovector.com in the section: Investors & Media.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from 7:00 am CEST the same day.

Northwest Biotherapeutics Announces $5 Million Financing

On August 21, 2020 Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that the Company has completed a non-dilutive debt financing for net proceeds of another $5 million (Press release, Northwest Biotherapeutics, AUG 21, 2020, View Source [SID1234563936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company anticipates that this financing will help further build the Company’s momentum by providing resources for expansion of production capacity and for ramp up of certain readiness activities as the Company approaches the readout of topline data from its Phase III trial of DCVax-L for Glioblastoma.

The Company entered into this 21-month Note (the "Loan") on August 17, 2020 for $5,505,000 at an 8% annualized interest rate, with no payments due for the first 7 months. Prepayment of the Loan can be made at any time with a 15% prepayment penalty. If the Loan remains outstanding past month 8, it will be amortized through month 21 with monthly payments of 110% of 14 equal monthly principal payments. The note also includes a $500,000 original issue discount. The lender is Iliad Research and Trading, LP.